Rankings / Metabolic Health

Survodutide

Metabolic Health · GLP-1/glucagon agonist (dual)

Tier B

Reviewed by Read Off Label · Last reviewed · How we grade

glp-1investigationalawaiting-readout
6.8 / 10
Tier B
Ev 8 Bn 8 Sf 5

Bottom line

Read Off Label grades Survodutide as B (6.8/10) based on strong evidence, high benefit magnitude, and a med-risk safety profile.

Boehringer Ingelheim/Zealand Pharma.

Studied, labeled, or reported-use context: 3. — Investigational; not individualized guidance.

What the evidence says

Boehringer Ingelheim/Zealand Pharma. SYNCHRONIZE-1 (no T2D) Phase 3 full results published in NEJM (Jun 2026, ADA Scientific Sessions): -16.6% mean body weight at 76 weeks vs -3.2% placebo (efficacy estimand), 85% achieving >=5% loss, loss driven predominantly by fat mass. SYNCHRONIZE-MASLD (Nature Medicine, Jun 8 2026; n=218, obesity + MASLD): met co-primary endpoints (>=30% MRI-PDFF liver-fat reduction and % body-weight change at 48 wk) -- 6 in 10 participants reached liver-fat normalization, the first dedicated MASLD Phase 3 readout for the class. SYNCHRONIZE-2 (with T2D, n=752) and the CVOT remain ongoing. Phase 2 (Le Roux 2024 Lancet) showed up to 19% weight loss.

Mechanism

Dual GLP-1 receptor and glucagon receptor agonist; glucagon arm increases energy expenditure and hepatic fat oxidation; particular interest for MASLD/metabolic liver disease

Studied, labeled, or reported dose & route

3.6 or 6.0 mg SC weekly (Phase 3 doses); titrated

This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.

Citations

A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.

Common questions

What does the evidence show about Survodutide's effects?
Read Off Label rates the evidence for Survodutide as Strong and the benefit magnitude as high, producing an overall grade of B (6.8/10). Boehringer Ingelheim/Zealand Pharma.
What safety findings are reported for Survodutide?
Survodutide has a med risk profile in the database. Med (similar GI profile to GLP-1 class; no unexpected signals to date) Legal status: Investigational (Phase 3).
What doses or routes are reported for Survodutide?
3.6 or 6.0 mg SC weekly (Phase 3 doses); titrated This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
How does Survodutide work?
Dual GLP-1 receptor and glucagon receptor agonist; glucagon arm increases energy expenditure and hepatic fat oxidation; particular interest for MASLD/metabolic liver disease

This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.